{"id":9863,"date":"2025-11-04T06:18:57","date_gmt":"2025-11-04T12:18:57","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=9863"},"modified":"2025-11-04T10:07:10","modified_gmt":"2025-11-04T16:07:10","slug":"nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ar\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/","title":{"rendered":"\u0623\u0639\u0644\u0646\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633 \u0639\u0646 \u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0633\u0644\u0627\u0645\u0629 \u0628\u0639\u062f \u062e\u0645\u0633 \u0633\u0646\u0648\u0627\u062a \u0645\u0646 \u062f\u0631\u0627\u0633\u0629 \u0627\u0644\u0645\u062a\u0627\u0628\u0639\u0629 \u0644\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u0623\u0648\u0644\u0649\/\u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0644\u0639\u0644\u0627\u062c MCO-010 \u0628\u062a\u0642\u0646\u064a\u0629 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0628\u0635\u0631\u064a \u0627\u0644\u0648\u0631\u0627\u062b\u064a \u0641\u064a \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a."},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u062f\u0627\u0644\u0627\u0633<\/span>,\u00a04 \u0646\u0648\u0641\u0645\u0628\u0631 2025<\/span>\u00a0 \u2014 \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u0644\u0644\u0639\u0644\u0627\u062c\u0627\u062a<\/a>\u00a0\u0623\u0639\u0644\u0646\u062a \u0627\u0644\u064a\u0648\u0645 \u0639\u0646 \u0646\u062a\u0627\u0626\u062c \u0633\u0644\u0627\u0645\u0629 \u0625\u064a\u062c\u0627\u0628\u064a\u0629 \u0637\u0648\u064a\u0644\u0629 \u0627\u0644\u0623\u062c\u0644 \u0645\u0646\u00a0\u064a\u0645\u062a\u062f<\/b>\u00a0\u062f\u0631\u0627\u0633\u0629\u060c \u0648\u0647\u064a \u0645\u062a\u0627\u0628\u0639\u0629 \u0644\u0645\u062f\u0629 \u062e\u0645\u0633 \u0633\u0646\u0648\u0627\u062a \u0644\u0644\u0645\u0634\u0627\u0631\u0643\u064a\u0646 \u0627\u0644\u0630\u064a\u0646 \u062a\u0644\u0642\u0648\u0627 \u062d\u0642\u0646\u0629 \u0648\u0627\u062d\u062f\u0629 \u062f\u0627\u062e\u0644 \u0627\u0644\u062c\u0633\u0645 \u0627\u0644\u0632\u062c\u0627\u062c\u064a \u0645\u0646 MCO-010 \u0641\u064a \u062a\u062c\u0631\u0628\u0629 \u0633\u0627\u0628\u0642\u0629 \u0645\u0646 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 1\/2a.\u00a0<\/p>

The EXTEND study followed ten participants with advanced retinitis pigmentosa (RP) who had previously received MCO-010, an optogenetic therapy designed to restore vision using Nanoscope’s proprietary Multi-Characteristic Opsin (MCO) platform.<\/p>

\u0623\u0643\u062f\u062a \u0634\u0631\u0643\u0629 EXTEND \u0623\u0646\u00a0\u062a\u064f\u0639\u062f \u0627\u0644\u062d\u0642\u0646\u0629 \u0627\u0644\u0648\u0627\u062d\u062f\u0629 \u062f\u0627\u062e\u0644 \u0627\u0644\u062c\u0633\u0645 \u0627\u0644\u0632\u062c\u0627\u062c\u064a \u0645\u0646 MCO-010 \u0622\u0645\u0646\u0629 \u0648\u064a\u062a\u062d\u0645\u0644\u0647\u0627 \u0627\u0644\u062c\u0633\u0645 \u062c\u064a\u062f\u064b\u0627 \u0639\u0644\u0649 \u0645\u062f\u0649 \u062e\u0645\u0633 \u0633\u0646\u0648\u0627\u062a<\/b>, \u062f\u0648\u0646 \u0623\u064a \u0622\u062b\u0627\u0631 \u062c\u0627\u0646\u0628\u064a\u0629 \u062e\u0637\u064a\u0631\u0629 \u0623\u0648 \u0645\u0624\u0634\u0631\u0627\u062a \u0633\u0644\u0627\u0645\u0629 \u062c\u062f\u064a\u062f\u0629\u060c \u0625\u0644\u0649 \u062c\u0627\u0646\u0628\u00a0\u0627\u0644\u062a\u062d\u0633\u064a\u0646\u0627\u062a \u0641\u064a \u062c\u0648\u062f\u0629 \u0627\u0644\u062d\u064a\u0627\u0629 \u0627\u0644\u062a\u064a \u0644\u0648\u062d\u0638\u062a \u062e\u0644\u0627\u0644 \u0646\u0641\u0633 \u0627\u0644\u0633\u0646\u0648\u0627\u062a \u0627\u0644\u062e\u0645\u0633<\/b>.<\/p>

\u0645\u0644\u0641 \u0623\u0645\u0627\u0646 \u0642\u0648\u064a \u0639\u0644\u0649 \u0627\u0644\u0645\u062f\u0649 \u0627\u0644\u0637\u0648\u064a\u0644<\/b><\/p>

\u0639\u0644\u0649 \u0645\u062f\u0649 \u062e\u0645\u0633 \u0633\u0646\u0648\u0627\u062a\u060c \u0638\u0644 \u0645\u0644\u0641 \u0627\u0644\u0633\u0644\u0627\u0645\u0629 \u0645\u062a\u0633\u0642\u064b\u0627 \u0628\u064a\u0646 \u062a\u062c\u0631\u0628\u0629 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 1\/2\u0623 \u0648\u0641\u062a\u0631\u0629 \u0627\u0644\u0645\u062a\u0627\u0628\u0639\u0629 \u0637\u0648\u064a\u0644\u0629 \u0627\u0644\u0623\u062c\u0644\u060c \u0645\u0639 \u0627\u0644\u062a\u0647\u0627\u0628 \u0639\u0627\u0628\u0631 \u064a\u0645\u0643\u0646 \u0627\u0644\u0633\u064a\u0637\u0631\u0629 \u0639\u0644\u064a\u0647\u060c \u0648\u0639\u062f\u0645 \u0648\u062c\u0648\u062f \u062d\u0627\u0644\u0627\u062a \u062a\u0648\u0642\u0641\u060c \u0648\u0639\u062f\u0645 \u0648\u062c\u0648\u062f \u0625\u0634\u0627\u0631\u0627\u062a \u0633\u0644\u0627\u0645\u0629 \u062c\u062f\u064a\u062f\u0629.<\/p>

“These results demonstrate the excellent long-term safety and tolerability of MCO-010, even five years after a single injection,” said\u00a0\u0633\u0627\u0645\u0627\u0631\u064a\u0646\u062f\u0631\u0627 \u0645\u0648\u0647\u0627\u0646\u062a\u064a\u060c \u0627\u0644\u062d\u0627\u0635\u0644 \u0639\u0644\u0649 \u062f\u0631\u062c\u0629 \u0627\u0644\u062f\u0643\u062a\u0648\u0631\u0627\u0647\u060c \u0631\u0626\u064a\u0633 \u0648\u0643\u0628\u064a\u0631 \u0627\u0644\u0645\u0633\u0624\u0648\u0644\u064a\u0646 \u0627\u0644\u0639\u0644\u0645\u064a\u064a\u0646 \u0641\u064a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628<\/a>. “The absence of serious safety signals and strong participant retention underscore the potential of MCO-010 as a durable, non-invasive therapy for severe vision loss RP patients.”<\/p>

\u0641\u0639\u0627\u0644\u064a\u0629 \u0645\u0633\u062a\u062f\u0627\u0645\u0629<\/b><\/p>

\u062e\u0644\u0627\u0644 \u0627\u0644\u062a\u062c\u0631\u0628\u0629 \u0627\u0644\u0623\u0648\u0644\u064a\u0629\u060c \u0623\u0638\u0647\u0631 \u0627\u0644\u0645\u0634\u0627\u0631\u0643\u0648\u0646 \u0627\u0644\u0630\u064a\u0646 \u062a\u0644\u0642\u0648\u0627 \u062c\u0631\u0639\u0629 \u0623\u0639\u0644\u0649 \u0645\u0646 MCO-010 \u062a\u062d\u0633\u0646\u0627\u064b \u0645\u0644\u062d\u0648\u0638\u0627\u064b \u0625\u062d\u0635\u0627\u0626\u064a\u0627\u064b \u0641\u064a \u062d\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0628\u0639\u062f \u0639\u0627\u0645 \u0648\u0627\u062d\u062f. \u0648\u0627\u0633\u062a\u0645\u0631 \u0627\u0644\u0645\u0634\u0627\u0631\u0643\u0648\u0646 \u0641\u064a \u0627\u0644\u0625\u0628\u0644\u0627\u063a \u0639\u0646\u00a0\u062c\u0648\u062f\u0629 \u062d\u064a\u0627\u0629 \u0645\u0633\u062a\u0642\u0631\u0629 \u0623\u0648 \u0645\u062d\u0633\u0651\u0646\u0629 \u0641\u064a\u0645\u0627 \u064a\u062a\u0639\u0644\u0642 \u0628\u0627\u0644\u0631\u0624\u064a\u0629<\/b>\u00a0\u0639\u0644\u0649 \u0645\u062f\u0649 \u0641\u062a\u0631\u0629 \u0627\u0644\u062e\u0645\u0633 \u0633\u0646\u0648\u0627\u062a\u060c \u0648\u062e\u0627\u0635\u0629 \u0641\u064a \u0627\u0644\u0623\u0646\u0634\u0637\u0629 \u0627\u0644\u062a\u064a \u062a\u062a\u0637\u0644\u0628 \u0645\u0633\u0627\u0641\u062a\u064a\u0646 \u0648\u062a\u062f\u0627\u0628\u064a\u0631 \u0627\u0644\u0627\u0633\u062a\u0642\u0644\u0627\u0644\u064a\u0629 \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0627\u0644\u0631\u0624\u064a\u0629.\u00a0<\/p>

\u062a\u0645 \u0639\u0631\u0636 \u0627\u0644\u0628\u064a\u0627\u0646\u0627\u062a \u0645\u0624\u062e\u0631\u0627\u064b \u0641\u064a\u00a034\u0630<\/sup>\u00a0\u0627\u0644\u0645\u0624\u062a\u0645\u0631 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u062c\u0645\u0639\u064a\u0629 \u062c\u0631\u0627\u062d\u0629 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0648\u0627\u0644\u062c\u0633\u0645 \u0627\u0644\u0632\u062c\u0627\u062c\u064a - \u0627\u0644\u0647\u0646\u062f<\/a>.<\/p>

\u0646\u0628\u0630\u0629 \u0639\u0646 \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633
<\/b>\u062a\u064f\u0637\u0648\u0651\u0631 \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633 \u0639\u0644\u0627\u062c\u064b\u0627 \u0628\u0635\u0631\u064a\u064b\u0627 \u0648\u0631\u0627\u062b\u064a\u064b\u0627 \u0644\u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631\u060c \u0628\u063a\u0636 \u0627\u0644\u0646\u0638\u0631 \u0639\u0646 \u0646\u0648\u0639 \u0627\u0644\u0645\u0631\u0636\u060c \u0644\u0645\u0644\u0627\u064a\u064a\u0646 \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u0641\u0642\u062f\u0648\u0627 \u0628\u0635\u0631\u0647\u0645 \u0646\u062a\u064a\u062c\u0629 \u0623\u0645\u0631\u0627\u0636 \u062a\u0646\u0643\u0633\u064a\u0629 \u0641\u064a \u0627\u0644\u0634\u0628\u0643\u064a\u0629. \u0648\u0642\u062f \u0628\u062f\u0623\u062a \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u0625\u062c\u0631\u0627\u0621\u0627\u062a \u062a\u0642\u062f\u064a\u0645 \u0637\u0644\u0628 \u062a\u0631\u062e\u064a\u0635 \u0628\u064a\u0648\u0644\u0648\u062c\u064a (BLA) \u0625\u0644\u0649 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 (FDA) \u0644\u0639\u0644\u0627\u062c \u0645\u0646\u062a\u062c\u0647\u0627 \u0627\u0644\u0631\u0626\u064a\u0633\u064a\u060c MCO-010\u060c \u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0634\u062f\u064a\u062f \u0644\u0644\u0628\u0635\u0631 \u0646\u062a\u064a\u062c\u0629 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a. \u0648\u0641\u064a \u062d\u0627\u0644 \u0627\u0644\u0645\u0648\u0627\u0641\u0642\u0629 \u0639\u0644\u064a\u0647\u060c \u064a\u064f\u062a\u0648\u0642\u0639 \u0623\u0646 \u064a\u0635\u0628\u062d MCO-010 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0642\u064a\u0627\u0633\u064a \u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a. \u0643\u0645\u0627 \u0623\u0638\u0647\u0631\u062a \u0627\u0644\u0634\u0631\u0643\u0629 \u0646\u062a\u0627\u0626\u062c \u0648\u0627\u0639\u062f\u0629 \u0644\u0627\u0633\u062a\u062e\u062f\u0627\u0645 MCO-010 \u0641\u064a \u0639\u0644\u0627\u062c \u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a. \u0648\u0642\u062f \u062d\u0635\u0644 MCO-010 \u0639\u0644\u0649 \u062a\u0635\u0646\u064a\u0641\u0627\u062a \u0627\u0644\u0645\u0633\u0627\u0631 \u0627\u0644\u0633\u0631\u064a\u0639 \u0648\u062f\u0648\u0627\u0621 \u0627\u0644\u064a\u062a\u064a\u0645 \u0645\u0646 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 \u0644\u0643\u0644 \u0645\u0646 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a \u0648\u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a\u060c \u0628\u0627\u0644\u0625\u0636\u0627\u0641\u0629 \u0625\u0644\u0649 \u062a\u0635\u0646\u064a\u0641 RMAT \u0644\u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a\u060c \u0648\u062a\u0635\u0646\u064a\u0641\u0627\u062a \u062f\u0648\u0627\u0621 \u0627\u0644\u064a\u062a\u064a\u0645 \u0645\u0646 \u0648\u0643\u0627\u0644\u0629 \u0627\u0644\u0623\u062f\u0648\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 \u0644\u062a\u063a\u0637\u064a\u0629 \u0636\u0645\u0648\u0631 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u063a\u064a\u0631 \u0627\u0644\u0645\u062a\u0644\u0627\u0632\u0645\u064a \u0648\u0627\u0644\u0645\u062a\u0644\u0627\u0632\u0645\u064a \u0627\u0644\u0630\u064a \u064a\u0647\u064a\u0645\u0646 \u0639\u0644\u064a\u0647 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0639\u0635\u0648\u064a\u0629 \u0648\u0627\u0644\u0645\u062e\u0631\u0648\u0637\u064a\u0629\u060c \u0648\u0636\u0645\u0648\u0631 \u0627\u0644\u0628\u0642\u0639\u0629 \u0627\u0644\u0635\u0641\u0631\u0627\u0621. \u0648\u0645\u0646 \u0627\u0644\u0645\u062a\u0648\u0642\u0639 \u0623\u0646 \u064a\u0628\u062f\u0623 \u0628\u0631\u0646\u0627\u0645\u062c \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0644\u0639\u0644\u0627\u062c MCO-010 \u0641\u064a \u0627\u0644\u0636\u0645\u0648\u0631 \u0627\u0644\u062c\u063a\u0631\u0627\u0641\u064a \u0628\u062d\u0644\u0648\u0644 \u0646\u0647\u0627\u064a\u0629 \u0639\u0627\u0645 2025.<\/p>

\u0627\u062a\u0635\u0627\u0644:
<\/b>\u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628
(817) 857-1186
PR@nanostherapeutics.com<\/a><\/p>

\u0627\u0644\u0645\u0635\u062f\u0631 \u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

DALLAS,\u00a0Nov. 4, 2025\u00a0 — Nanoscope Therapeutics Inc.\u00a0announced today positive long-term safety results from its\u00a0EXTEND\u00a0study, a five-year follow-up of participants who received a single intravitreal injection of MCO-010 in an earlier Phase 1\/2a trial.\u00a0 The EXTEND study followed ten participants with advanced retinitis pigmentosa (RP) who had previously received MCO-010, an optogenetic therapy designed to restore […]<\/p>\n","protected":false},"author":6,"featured_media":8971,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-9863","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics Reports Five-Year Safety Results from Phase 1\/2a Follow-Up Study of MCO-010 Optogenetic Therapy in Retinitis Pigmentosa - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ar\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/\" \/>\n<meta property=\"og:locale\" content=\"ar_AR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Reports Five-Year Safety Results from Phase 1\/2a Follow-Up Study of MCO-010 Optogenetic Therapy in Retinitis Pigmentosa - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ar\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-04T12:18:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-04T16:07:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631\" \/>\n\t<meta name=\"twitter:data2\" content=\"\u062f\u0642\u064a\u0642\u062a\u0627\u0646\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/04\\\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/04\\\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Reports Five-Year Safety Results from Phase 1\\\/2a Follow-Up Study of MCO-010 Optogenetic Therapy in Retinitis Pigmentosa\",\"datePublished\":\"2025-11-04T12:18:57+00:00\",\"dateModified\":\"2025-11-04T16:07:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/04\\\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\\\/\"},\"wordCount\":408,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/04\\\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ar\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/04\\\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/04\\\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\\\/\",\"name\":\"Nanoscope Therapeutics Reports Five-Year Safety Results from Phase 1\\\/2a Follow-Up Study of MCO-010 Optogenetic Therapy in Retinitis Pigmentosa - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/04\\\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/04\\\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"datePublished\":\"2025-11-04T12:18:57+00:00\",\"dateModified\":\"2025-11-04T16:07:10+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/04\\\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\\\/#breadcrumb\"},\"inLanguage\":\"ar\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/04\\\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/04\\\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"width\":1200,\"height\":242},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/04\\\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Reports Five-Year Safety Results from Phase 1\\\/2a Follow-Up Study of MCO-010 Optogenetic Therapy in Retinitis Pigmentosa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ar\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633 \u062a\u064f\u0639\u0644\u0646 \u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0633\u0644\u0627\u0645\u0629 \u0628\u0639\u062f \u062e\u0645\u0633 \u0633\u0646\u0648\u0627\u062a \u0645\u0646 \u062f\u0631\u0627\u0633\u0629 \u0627\u0644\u0645\u062a\u0627\u0628\u0639\u0629 \u0644\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u0623\u0648\u0644\u0649\/\u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0644\u0639\u0644\u0627\u062c MCO-010 \u0628\u062a\u0642\u0646\u064a\u0629 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0628\u0635\u0631\u064a \u0627\u0644\u0648\u0631\u0627\u062b\u064a \u0641\u064a \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a - \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633","description":"\u062a\u064f\u0639\u062f\u0651 \u0645\u0646\u0635\u0629 \u0627\u0644\u0623\u0648\u0628\u0633\u064a\u0646 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u062e\u0635\u0627\u0626\u0635 (MCO) \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0646\u0627 \u0627\u0644\u0623\u0648\u0644\u0649 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0627\u0644\u062a\u064a \u0623\u062b\u0628\u062a\u062a \u0642\u062f\u0631\u062a\u0647\u0627 \u0639\u0644\u0649 \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0644\u0645\u0631\u0636\u0649 \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0634\u062f\u064a\u062f \u0644\u0644\u0628\u0635\u0631 \u0641\u064a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629. \u0648\u0642\u062f \u0637\u0648\u0651\u0631\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062a\u0642\u0646\u064a\u0629 MCO-010\u060c \u0648\u0647\u064a \u0627\u0644\u062a\u0642\u0646\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u0649 \u0648\u0627\u0644\u0648\u062d\u064a\u062f\u0629 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0641\u064a \u0645\u062c\u0627\u0644 \u0639\u0644\u0645 \u0627\u0644\u0628\u0635\u0631\u064a\u0627\u062a \u0627\u0644\u0648\u0631\u0627\u062b\u064a\u0629\u060c \u0648\u0627\u0644\u062a\u064a \u062a\u062a\u0645\u064a\u0632 \u0628\u0646\u0637\u0627\u0642\u0647\u0627 \u0627\u0644\u0648\u0627\u0633\u0639 \u0648\u0627\u0633\u062a\u062c\u0627\u0628\u062a\u0647\u0627 \u0627\u0644\u0633\u0631\u064a\u0639\u0629 \u0648\u062d\u0633\u0627\u0633\u064a\u062a\u0647\u0627 \u0627\u0644\u0641\u0627\u0626\u0642\u0629\u060c \u0648\u0647\u064a \u062a\u0642\u0646\u064a\u0629 \u0645\u0633\u062a\u0642\u0644\u0629 \u0639\u0646 \u0627\u0644\u062c\u064a\u0646\u0627\u062a \u0627\u0644\u0645\u0633\u062a\u062e\u062f\u0645\u0629 \u0641\u064a \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ar\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/","og_locale":"ar_AR","og_type":"article","og_title":"Nanoscope Therapeutics Reports Five-Year Safety Results from Phase 1\/2a Follow-Up Study of MCO-010 Optogenetic Therapy in Retinitis Pigmentosa - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ar\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2025-11-04T12:18:57+00:00","article_modified_time":"2025-11-04T16:07:10+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629":"Nanoscope Therapeutics","\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631":"\u062f\u0642\u064a\u0642\u062a\u0627\u0646"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Reports Five-Year Safety Results from Phase 1\/2a Follow-Up Study of MCO-010 Optogenetic Therapy in Retinitis Pigmentosa","datePublished":"2025-11-04T12:18:57+00:00","dateModified":"2025-11-04T16:07:10+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/"},"wordCount":408,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ar"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/","url":"https:\/\/nanostherapeutics.com\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/","name":"\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633 \u062a\u064f\u0639\u0644\u0646 \u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0633\u0644\u0627\u0645\u0629 \u0628\u0639\u062f \u062e\u0645\u0633 \u0633\u0646\u0648\u0627\u062a \u0645\u0646 \u062f\u0631\u0627\u0633\u0629 \u0627\u0644\u0645\u062a\u0627\u0628\u0639\u0629 \u0644\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u0623\u0648\u0644\u0649\/\u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0644\u0639\u0644\u0627\u062c MCO-010 \u0628\u062a\u0642\u0646\u064a\u0629 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0628\u0635\u0631\u064a \u0627\u0644\u0648\u0631\u0627\u062b\u064a \u0641\u064a \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a - \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","datePublished":"2025-11-04T12:18:57+00:00","dateModified":"2025-11-04T16:07:10+00:00","description":"\u062a\u064f\u0639\u062f\u0651 \u0645\u0646\u0635\u0629 \u0627\u0644\u0623\u0648\u0628\u0633\u064a\u0646 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u062e\u0635\u0627\u0626\u0635 (MCO) \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0646\u0627 \u0627\u0644\u0623\u0648\u0644\u0649 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0627\u0644\u062a\u064a \u0623\u062b\u0628\u062a\u062a \u0642\u062f\u0631\u062a\u0647\u0627 \u0639\u0644\u0649 \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0644\u0645\u0631\u0636\u0649 \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0634\u062f\u064a\u062f \u0644\u0644\u0628\u0635\u0631 \u0641\u064a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629. \u0648\u0642\u062f \u0637\u0648\u0651\u0631\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062a\u0642\u0646\u064a\u0629 MCO-010\u060c \u0648\u0647\u064a \u0627\u0644\u062a\u0642\u0646\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u0649 \u0648\u0627\u0644\u0648\u062d\u064a\u062f\u0629 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0641\u064a \u0645\u062c\u0627\u0644 \u0639\u0644\u0645 \u0627\u0644\u0628\u0635\u0631\u064a\u0627\u062a \u0627\u0644\u0648\u0631\u0627\u062b\u064a\u0629\u060c \u0648\u0627\u0644\u062a\u064a \u062a\u062a\u0645\u064a\u0632 \u0628\u0646\u0637\u0627\u0642\u0647\u0627 \u0627\u0644\u0648\u0627\u0633\u0639 \u0648\u0627\u0633\u062a\u062c\u0627\u0628\u062a\u0647\u0627 \u0627\u0644\u0633\u0631\u064a\u0639\u0629 \u0648\u062d\u0633\u0627\u0633\u064a\u062a\u0647\u0627 \u0627\u0644\u0641\u0627\u0626\u0642\u0629\u060c \u0648\u0647\u064a \u062a\u0642\u0646\u064a\u0629 \u0645\u0633\u062a\u0642\u0644\u0629 \u0639\u0646 \u0627\u0644\u062c\u064a\u0646\u0627\u062a \u0627\u0644\u0645\u0633\u062a\u062e\u062f\u0645\u0629 \u0641\u064a \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/#breadcrumb"},"inLanguage":"ar","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/"]}]},{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nanostherapeutics.com\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","width":1200,"height":242},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Reports Five-Year Safety Results from Phase 1\/2a Follow-Up Study of MCO-010 Optogenetic Therapy in Retinitis Pigmentosa"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628","description":"\u0625\u0639\u0627\u062f\u0629 \u0646\u0648\u0631 \u0627\u0644\u0623\u0645\u0644","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ar"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"\u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/9863","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/comments?post=9863"}],"version-history":[{"count":7,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/9863\/revisions"}],"predecessor-version":[{"id":9870,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/9863\/revisions\/9870"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/media\/8971"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/media?parent=9863"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/categories?post=9863"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/tags?post=9863"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}